MAKE THE MOVE TO APRISO

    APRISO offers a range of resources to help keep your patients in remission.

    UCan Patient Support Program

    Managing a chronic disease like ulcerative colitis (UC) can be a real challenge for you and your patients. Fortunately, there’s UCan—a patient support program that may help educate your patients and keep them on track. The program includes:

    • Online information about UC
    • Tips to keep your patients on track, such as tools for remembering to take their medication and tips for traveling

    Adherence Support

    Sometimes people with UC think that they only need to take their medication when they experience symptoms. These support tools will help your patients follow their prescribed treatment plan.

    • APRISO refill and dosing reminders by text or email
    • Emails with tips for staying on treatment

    Visit the APRISO patient website for more information on the UCan program at www.aprisorx.com/ucan.

    APRISO Instant Savings Card

    With the APRISO Instant Savings Card, most eligible commercially insured patients may pay a $0 co-pay or out-of-pocket expense on their first APRISO prescription and $10 co-pays or out-of-pocket expense on all future prescriptions.* Eligible patients can sign up for the APRISO Instant Savings Card by visiting the APRISO patient website at www.aprisorx.com/apriso/savings-card.

    * Maximum benefit of $110 off the first use; maximum benefit of $100 off each subsequent use. Federally insured patients are not eligible. Please see full eligibility criteria, terms and conditions contained on the reverse of the Instant Savings Card or on the APRISO patient website located at www.aprisorx.com.

     

    Doctor Discussion Guide

    An interactive and customized conversation starter that can help your patients prepare for their appointments and feel more comfortable talking about their UC.

    Download now

    UC Symptom Tracker

    A 7-day symptom tracker to help your patients monitor and document their disease.

    Download now

    Ulcerative Colitis for Dummies®†

    This free tool teaches patients the basics about living with UC by helping them understand their symptoms, answering common questions about UC, and offering advice on how to manage their disease.

    Download a copy by visiting www.ucfordummies.com

    APRISO Patient Brochure Booklet

    This brochure helps patients learn about APRISO, and includes information on

    • Maintaining UC remission
    • APRISO dosing and mechanism of action (MOA)
    • The APRISO Instant Savings Card Program
    • The UCan Patient Support Program
    Download pdf
    For Dummies is a licensed trademark of John Wiley & Sons, Inc.

    INDICATION

    APRISO® (mesalamine) extended-release capsules are indicated for the maintenance of remission of ulcerative colitis (UC) in patients 18 years of age and older.

    IMPORTANT SAFETY INFORMATION—APRISO extended-release capsules

    • APRISO extended-release capsules are contraindicated in patients with hypersensitivity to salicylates or aminosalicylates, or to any of the components of APRISO capsules.
    • Renal impairment, including minimal change nephropathy, acute and chronic interstitial nephritis, and, rarely, renal failure, has been reported in patients given products such as APRISO that contain mesalamine or are converted to mesalamine. It is recommended that patients have an evaluation of renal function prior to initiation of APRISO therapy and periodically while on therapy. Exercise caution when using APRISO in patients with known renal dysfunction or a history of renal disease.
    • Mesalamine has been associated with an acute intolerance syndrome that may be difficult to distinguish from a flare of inflammatory bowel disease. Symptoms include cramping, acute abdominal pain and bloody diarrhea, sometimes fever, headache, and rash. If acute intolerance syndrome is suspected, promptly discontinue treatment with APRISO.
    • There have been reports of hepatic failure in patients with pre-existing liver disease who have been administered mesalamine. Caution should be exercised when administering APRISO to patients with liver disease.
    • In clinical studies, the most common adverse reactions (occurring in ≥3% of APRISO patients and at a greater rate than placebo) were headache (11%), diarrhea (8%), upper abdominal pain (5%), nausea (4%), nasopharyngitis (4%), influenza and influenza-like illness (4%), and sinusitis (3%).
    • Because dissolution of the coating of APRISO granules depends on pH, APRISO should not be co-administered with antacids.
    • Because of the potential for blood dyscrasias in patients 65 years and older, caution should be taken to closely monitor blood cell counts during mesalamine therapy in these patients.
    • Inform patients with phenylketonuria (PKU) or their caregivers that each APRISO capsule contains aspartame equivalent to 0.56 mg of phenylalanine, so that the recommended adult dosing provides an equivalent of 2.24 mg of phenylalanine per day.

    To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-508-0024 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

    Please click here for full Prescribing Information for APRISO extended-release capsules.

    For product information, adverse event reports, and product complaint reports, please contact:

    Salix Product Information Call Center
    Phone: 1-800-508-0024
    Fax: 1-510-595-8183
    Email: salixmc@dlss.com